ESPE Abstracts (2016) 86 P-P1-809

Early Treatment with rhGH in Patients with Prader-Willi Syndrome Results in Improved Height with No Respiratory Adverse Effects

Kyriaki Alatzogloua, Mahalakshmi Gopalakushnamoorthya, Emily Trewellaa, Aayesha Mullaa, Hui-Leng Tanb & Nicola Bridgesa

aChelsea & Westminster Hospital, London, UK; bRoyal Brompton & Harefield Hospital, London, UK

Background: Prader-Willi syndrome (PWS) is a complex genetic disorder caused by lack of expression of paternally inherited imprinted genes on Chr15q11-q13. rhGH has beneficial effects on growth, body composition and development. Starting age, dose titration and monitoring remain controversial.

Objective: To study retrospectively children who presented in our multidisciplinary PWS clinic and assess response to rhGH treatment, auxology, IGF1 concentration and potential complications.

Method & Patients: In total of 47 patients (male 27, female 20) were followed up; 5/47 were lost to follow-up and 2/47 refused rhGH treatment. 40 patients were treated with rhGH, all had detailed sleep studies before, and six weeks after starting treatment.

Results: Treatment started at a mean age of 2.1±2.6 years (range 0.58–12.8), 45% of patients (n=18) started rhGH before the age of one (0.58–0.97 years). 15% (n=6) had evidence of sleep apnoea, requiring non invasive ventilation before starting rhGH. Mean starting rhGH dose was 0.025 mg/kg per day (0.5 mg/m2 per day) increased to 1 mg/m2 per day following the second sleep study. At one year, mean dose was 0.7±0.2 mg/m2 per day. Pre-treatment mean height was −1.65±1.1 SDS (−4.47 to 0.37 SDS), with a weight of −1.43±1.8 SDS (−5.5 to 3.3) and BMI of −0.46±1.6 SDS (−3 to 4). After one year there was an increase of 1.37SDS in Ht (mean −0.28±0.94, range −2.4 to +2.3), with a mean weight of −0.24±1.8 SDS (range −4.0 to 3.7) and BMI of 0.08±2 SDS (−3.0 to 4.6). No patient had worsening respiratory status and 2/6 patients discontinued ventilatory support. IGF1 was >+2.0 SDS in 60% and the dose of rhGH remained unchanged with repeat yearly IGF1 measurement. One patient stopped treatment (pause in treatment during spinal surgery).

Conclusion: Early treatment with GH results in improved height in the first year with no adverse effect on respiratory function. We recommend dose titration using auxology and IGF1 concentration.

Article tools

My recent searches

No recent searches.